Cristina Cardona-Barreña
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Cristina Cardona-Barreña has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Ahmed El-Shater Bosaily
Division of Surgery and Interventional Science, Department of Urology, University College London Hospital, 235 Euston Road, London, NW1 2BU, UK
1 shared publicationAiman Haider
Department of Pathology, University College London Hospital, 60 Whitfield Street, London, W1T4EU, UK
1 shared publication- Alasdair J. Taylor
Department of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University
1 shared publication Alastair Henderson
Department of Urology, Maidstone and Tunbridge Wells NHS Trust, Hermitage Lane, Tunbridge Wells, ME16 9QQ, UK
1 shared publicationAlex Freeman
Department of Pathology, University College London Hospital, 60 Whitfield Street, London, W1T4EU, UK
1 shared publicationAlex Kirkham
Centre for Medical Image Computing, University College London, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK
1 shared publication
Latest Publications
- Open Access
- 19 November 2025
- Published by MDPI AG in Preprints.org
From Signals to Shields: Dual-Impact Germline Variants Implicated in FGF/FGFR Signaling in Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a cancer of the bile duct epithelium, which is increasingly associated with chronic inflammation and/or cholestasis. In recent years, fibroblast growth factor (FGF) signaling has gained substantial interest in CCA with three U.S. Food and Drug Administration (FDA)-approved drugs currently available for targeted inhibition of FGF receptors (FGFRs). FGF signaling is implicated in various aspects of CCA tumorigenesis, influencing immune responses and correlating with less favorable therapeutic outcomes. Despite some progress in our understanding of the genetic underpinnings of CCA over the past decade, the contribution of patient-intrinsic germline variations implicated in FGF/FGFR signaling had not been systematically explored. Here, we explore the hypothesis that the dual impact of germline variants pleiotropically associated with the FGFR signaling pathway acts both as signals promoting tumorigenesis (tumor-intrinsic) and as shields protecting tumors from targeted immune response (tumor-extrinsic). This dualistic behavior sheds insights into the intricate interplay between genetic predisposition and pleiotropic factors in CCA pathogenesis, potentially impacting the prognosis of targeted therapies and immune checkpoint blockade therapies.
- 19 November 2025
- Published by MDPI AG in Preprints.org
Open AccessFrom Signals to Shields: Dual-Impact Germline Variants Implicated in FGF/FGFR Signaling in Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a cancer of the bile duct epithelium, which is increasingly associated with chronic inflammation and/or cholestasis. In recent years, fibroblast growth factor (FGF) signaling has gained substantial interest in CCA with three U.S. Food and Drug Administration (FDA)-approved drugs currently available for targeted inhibition of FGF receptors (FGFRs). FGF signaling is implicated in various aspects of CCA tumorigenesis, influencing immune responses and correlating with less favorable therapeutic outcomes. Despite some progress in our understanding of the genetic underpinnings of CCA over the past decade, the contribution of patient-intrinsic germline variations implicated in FGF/FGFR signaling had not been systematically explored. Here, we explore the hypothesis that the dual impact of germline variants pleiotropically associated with the FGFR signaling pathway acts both as signals promoting tumorigenesis (tumor-intrinsic) and as shields protecting tumors from targeted immune response (tumor-extrinsic). This dualistic behavior sheds insights into the intricate interplay between genetic predisposition and pleiotropic factors in CCA pathogenesis, potentially impacting the prognosis of targeted therapies and immune checkpoint blockade therapies.
- Open Access
- 21 July 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (30)
A preclinical pig model of Angelman syndrome mirrors the early developmental trajectory of the human condition
Angelman syndrome is a neurodevelopmental disorder characterized by severe motor and cognitive deficits. It is caused by the loss of the maternally inherited allele of the imprinted ubiquitin-protein ligase E3A ( UBE3A ) gene. Rodent models of Angelman syndrome do not fully recapitulate all the symptoms associated with the condition and are limited as a preclinical model for therapeutic development. Here, we show that pigs ( Sus scrofa ) with a maternally inherited deletion of UBE3A ( UBE3A -/+ ) have altered postnatal behaviors, impaired vocalizations, reduced brain growth, motor incoordination, and ataxia. Neonatal UBE3A -/+ pigs exhibited several symptoms observed in infants with Angelman syndrome, including hypotonia, suckling deficits, and failure to thrive. Collectively, these findings are consistent with the pathophysiology and developmental trajectory observed in individuals with Angelman syndrome. We anticipate that this pig model will advance our understanding of the pathophysiology of Angelman syndrome and be used as a preclinical large animal model for therapeutic development.
- 21 July 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (30)
Open AccessA preclinical pig model of Angelman syndrome mirrors the early developmental trajectory of the human condition
Angelman syndrome is a neurodevelopmental disorder characterized by severe motor and cognitive deficits. It is caused by the loss of the maternally inherited allele of the imprinted ubiquitin-protein ligase E3A ( UBE3A ) gene. Rodent models of Angelman syndrome do not fully recapitulate all the symptoms associated with the condition and are limited as a preclinical model for therapeutic development. Here, we show that pigs ( Sus scrofa ) with a maternally inherited deletion of UBE3A ( UBE3A -/+ ) have altered postnatal behaviors, impaired vocalizations, reduced brain growth, motor incoordination, and ataxia. Neonatal UBE3A -/+ pigs exhibited several symptoms observed in infants with Angelman syndrome, including hypotonia, suckling deficits, and failure to thrive. Collectively, these findings are consistent with the pathophysiology and developmental trajectory observed in individuals with Angelman syndrome. We anticipate that this pig model will advance our understanding of the pathophysiology of Angelman syndrome and be used as a preclinical large animal model for therapeutic development.
- Open Access
- 14 October 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-9
A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists
Gleason score 7 prostate cancer with a higher proportion of pattern 4 (G4) has been linked to genomic heterogeneity and poorer patient outcome. The current assessment of G4 proportion uses estimation by a pathologist, with a higher proportion of G4 more likely to trigger additional imaging and treatment over active surveillance. This estimation method has been shown to have inter-observer variability. Fifteen patients with Prostate Grade Group (GG) 2 (Gleason 3 + 4) and fifteen patients with GG3 (Gleason 4 + 3) disease were selected from the PROMIS study with 192 haematoxylin and eosin-stained slides scanned. Two experienced uropathologists assessed the maximum cancer core length (MCCL) and G4 proportion using the current standard method (visual estimation) followed by detailed digital manual annotation of each G4 area and measurement of MCCL (planimetric estimation) using freely available software by the same two experts. We aimed to compare visual estimation of G4 and MCCL to a pathologist-driven digital measurement. We show that the visual and digital MCCL measurement differs up to 2 mm in 76.6% (23/30) with a high degree of agreement between the two measurements; Visual gave a median MCCL of 10 ± 2.70 mm (IQR 4, range 5–15 mm) compared to digital of 9.88 ± 3.09 mm (IQR 3.82, range 5.01–15.7 mm) ( p = 0.64) The visual method for assessing G4 proportion over-estimates in all patients, compared to digital measurements [median 11.2% (IQR 38.75, range 4.7–17.9%) vs 30.4% (IQR 18.37, range 12.9–50.76%)]. The discordance was higher as the amount of G4 increased (Bias 18.71, CI 33.87–48.75, r 0.7, p < 0.0001). Further work on assessing actual G4 burden calibrated to clinical outcomes might lead to the use of differing G4 thresholds of significance if the visual estimation is used or by incorporating semi-automated methods for G4 burden measurement.
- 14 October 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-9
Open AccessA critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists
Gleason score 7 prostate cancer with a higher proportion of pattern 4 (G4) has been linked to genomic heterogeneity and poorer patient outcome. The current assessment of G4 proportion uses estimation by a pathologist, with a higher proportion of G4 more likely to trigger additional imaging and treatment over active surveillance. This estimation method has been shown to have inter-observer variability. Fifteen patients with Prostate Grade Group (GG) 2 (Gleason 3 + 4) and fifteen patients with GG3 (Gleason 4 + 3) disease were selected from the PROMIS study with 192 haematoxylin and eosin-stained slides scanned. Two experienced uropathologists assessed the maximum cancer core length (MCCL) and G4 proportion using the current standard method (visual estimation) followed by detailed digital manual annotation of each G4 area and measurement of MCCL (planimetric estimation) using freely available software by the same two experts. We aimed to compare visual estimation of G4 and MCCL to a pathologist-driven digital measurement. We show that the visual and digital MCCL measurement differs up to 2 mm in 76.6% (23/30) with a high degree of agreement between the two measurements; Visual gave a median MCCL of 10 ± 2.70 mm (IQR 4, range 5–15 mm) compared to digital of 9.88 ± 3.09 mm (IQR 3.82, range 5.01–15.7 mm) ( p = 0.64) The visual method for assessing G4 proportion over-estimates in all patients, compared to digital measurements [median 11.2% (IQR 38.75, range 4.7–17.9%) vs 30.4% (IQR 18.37, range 12.9–50.76%)]. The discordance was higher as the amount of G4 increased (Bias 18.71, CI 33.87–48.75, r 0.7, p < 0.0001). Further work on assessing actual G4 burden calibrated to clinical outcomes might lead to the use of differing G4 thresholds of significance if the visual estimation is used or by incorporating semi-automated methods for G4 burden measurement.